Cerebral Cavernous Malformation (CCM) is a vascular disease that affects the central nervous system, which familial form is due to autosomal dominant mutations in the genes KRIT1/CCM1, MGC4607/CCM2 and PDCD10/CCM3. Patients affected by the PDCD10 mutations usually have the onset of symptoms at an early age and a more aggressive phenotype. To contribute to knowledge about the disease, we performed clinical, functional, and neuroradiological analyses of the mutations in PDCD10/CCM3 in two patients comparing the findings with five patients with familial form from CCM1/KRIT1 or CCM2/MGC4607 mutations and six patients with sporadic form. In addition, we have evaluated the PDCD10/CCM3 gene expression by qPCR and developed a bioinformatic pipeline to assist in the possible clinical. The two CCM3 patients had an early onset of symptoms and a high lesion burden. Furthermore, the sequencing showed that P1 had a frameshift mutation (c.222delT;p.Asn75ThrfsTer14) and P2 a variant on the splicing region c.475-2A > G (p.A119Gfs*42). The mRNA expression was 4-fold lower in both patients with PDCD10/CCM3 mutation. In silico analysis, the prediction reveals that the frameshift mutation transcript lacks the C-terminal FAT-homology domain compared to the 212 aa-length wild-type PDCD10/CCM3 and preserves the N-terminal dimerization domain. We also demonstrated a related pathway that might explain the interplay between low-grade astrocytomas and PDCD10 CCM, a possible manifestation of the syndromic disease. The two mutations support the understanding of the protein-protein interaction between PDCD10 and several essential cellular proteins that might contribute to the mechanistic understanding of why some individuals with CCM3 have a syndromic phenotype.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.